UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

SERUM IGG4/IGG RATIO MAY OUTPERFORM SERUM IGG4 ALONE IN THE DIAGNOSIS OF TYPE 1 AUTOIMMUNE PANCREATITIS (AIP): A RETROSPECTIVE COHORT STUDY IN SINGAPORE

Xiu Ying Loo 1, Choon Guan Chua 1, Weida Chew 1

Affiliations

1 Tan Tock Seng Hospital, Singapore, Singapore

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Type 1 AIP is the most common presentation of IgG4-related disease. Serum IgG4 levels are widely used in initial screening and diagnosis, with levels ≥135 mg/dL recommended as part of the diagnostic criteria. However, its diagnostic specificity is limited as it can be elevated in a broad spectrum of neoplastic, infectious, and autoimmune diseases. Histological diagnosis though definitive, remains challenging in real life clinical practice. In recent years, IgG4/IgG ratio has been proposed as a promising alternative serum biomarker.

Aims & Methods

We aimed to study the diagnostic utility of serum IgG4/IgG ratio compared to serum IgG4 alone in the diagnosis of Type 1 AIP. We identified a cohort of patients from 2015 to 2021 who had raised serum IgG4 levels in Tan Tock Seng Hospital, Singapore. Associations between serum IgG4 level and IgG4/IgG ratio were compared to confirmed AIP diagnosis and characteristic computed tomography (CT) and magnetic resonance imaging (MRI) features (diffuse pancreatic swelling, rim-like enhancement). Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated at IgG4/IgG thresholds of ≥15% and ≥20%.

Results

Our sample included a total of 60 patients with raised serum IgG4 levels. 21 patients had been diagnosed with Type 1 AIP, and 39 patients had not.
The majority of our patients had serum IgG4 ≥135 mg/dL (n=53, 88.3%). However, there was no significant association between the conventional serum IgG4 cut off of ≥135 mg/dL and the diagnosis of AIP (p = 0.687). In contrast, serum IgG4/IgG ratio demonstrated significantly higher values in patients with AIP compared to those without (median 23.2% vs 13.9%; p < 0.001). Analysis by logistic regression of IgG4/IgG ratio showed an acceptable performance with an area under the curve of 0.779, sensitivity of 92.3%, and specificity of 52.4%.

Variable	Type 1 AIP Present (n=21)	Type 1 AIP Absent (n=39)	Test Statistic	p-value
IgG4/IgG ratio	23.2 (24.0 ± 14.2)	13.9 (13.4 ± 4.5)	U = 184	<0.001
Serum IgG4 ≥135 mg/dL	18/21 (85.7%)	35/39 (89.7%)	Fisher's exact	0.687

We performed further analysis to determine a threshold for diagnostic utility of serum IgG4/IgG ratio. A ratio of ≥20% was strongly associated with AIP diagnosis (OR = 13.2, 95% CI: 3.08–56.5; p < 0.001), with high specificity (92.3%) and PPV (78.6%). Reducing the diagnostic threshold to ≥15% increased sensitivity to 76.2% (vs 52.4% at ≥20%) and improved NPV 84.4%, however this reduced specificity to 69.2%.

Subset analysis was performed among patients with Type 1 AIP (n=21) to evaluate for relationship between serum biomarkers and typical imaging findings (diffuse pancreatic swelling, rim-like enhancement). When stratified to a cut off of ≥135 mg/dL, the association between serum IgG4 levels with imaging findings trended towards positivity, but was not statistically significant (OR 3.14, p = 0.0553, φ 0.196). The IgG4/IgG ratio demonstrated a stronger association with typical imaging findings, although still not achieving statistical significance (OR = 1.065, p = 0.129). This subset analysis is likely limited by the small sample size.

Conclusion

This study demonstrates that serum IgG4/IgG ratio is a superior serological marker compared to serum IgG4 alone, particularly in the diagnosis of type 1 AIP. A threshold ratio of ≥20% demonstrated strong association with AIP diagnosis, with high specificity and PPV.
Our findings support the incorporation of IgG4/IgG ratio - particularly at a cut-off of 20% - as a valuable adjunct in diagnosis of suspected type 1 AIP, and we recommend further research in a larger cohort to validate this data.

References

1. Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol. 2020;72(1):7–19.
2. Umehara H, Okazaki K, Kawa S, Takahashi H, Yoshino T, Matsui S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-related disease. Mod Rheumatol. 2021;31(3):529–33.
3. Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4-related disease. BMJ. 2020;369:m1067.
4. Uchida K, Okazaki K. Current status of type 1 (IgG4-related) autoimmune pancreatitis. J Gastroenterol. 2022;57(10):695–708.
5. Xia CS, Zhang S, Duan L, Zhao CW, Zhang F. Diagnostic performances of serum IgG4 concentration and IgG4/IgG ratio in IgG4-related disease. Clin Rheumatol. 2017;36(11):2769–74.

Conference

UEG Week Berlin 2025

Topics

Pancreas

Submission format

Abstract

Session

Acute pancreatitis: Complications and consequences (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Teaming up with pharma? Re-use of pre-clinical and clinical trial data - Clinical and pharmaceutical perspective

Geert R. D'Haens

INVESTIGATION OF ABCC6 GENETIC VARIANTS IN A COHORT OF CHOLESTATIC LIVER DISEASE PATIENTS USING WHOLE EXOME SEQUENCING

Carola Dröge

SERUM IGG4/IGG RATIO MAY OUTPERFORM SERUM IGG4 ALONE IN THE DIAGNOSIS OF TYPE 1 AUTOIMMUNE PANCREATITIS (AIP): A RETROSPECTIVE COHORT STUDY IN SINGAPORE

Weida Chew

Endoscopy in pancreatic NENs: Detection, RFA and beyond

Jean-Luc Van Laethem

Immunomodulation through neoadjuvant chemotherapy in pancreatic cancer

Lena Seifert

SHOULD PANCREATIC CANCER SURVEILLANCE BE OFFERED TO INDIVIDUALS WITH FAMILIAL ADENOMATOUS POLYPOSIS: RISK AND COST-EFFECTIVENESS ANALYSES

Derk Klatte

	Stent group (n-34)	No stent group (n-32)	P value
Primary outcome
Recurrence of CBDS	7(20.59%)	3(9.38%)	0.306
Secondary outcomes
Biliary and pancreatic complications -Jaundice -Cholangitis -Cholecystitis -Pancreatitis	0 0 2 0	0 0 0 0	0.164
Need for repeat ERC	6(18.18%)	3(9.38%)	0.475
Post ERC pancreatitis	3	0	0.085

			Cumulative incidence
Data	N (persons year)	PDAC cases	Age 60 years (95%)	Age 70 years (95%)
US	355 (10359.1)	1	0%	1.3% (0.2-8.4)
NL	1000 (41343.1)	4	0.4% (0.1-1.2)	0.6% (0.2-1.7)
Both	1355 (51702.2)	5	0.3% (0.1-0.9)	0.7% (0.3-1.8)

UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Most popular content

Rate for better recommendations!

ROLE OF PROPHYLACTIC BILIARY STENT IN REDUCING RECURRENCE OF STONES AND BILIARY COMPLICATIONS AFTER STONE CLEARANCE IN PATIENTS AWAITING CHOLECYSTECTOMY-A RANDOMIZED CONTROLLED TRIAL

Teaming up with pharma? Re-use of pre-clinical and clinical trial data - Clinical and pharmaceutical perspective

INVESTIGATION OF ABCC6 GENETIC VARIANTS IN A COHORT OF CHOLESTATIC LIVER DISEASE PATIENTS USING WHOLE EXOME SEQUENCING

SERUM IGG4/IGG RATIO MAY OUTPERFORM SERUM IGG4 ALONE IN THE DIAGNOSIS OF TYPE 1 AUTOIMMUNE PANCREATITIS (AIP): A RETROSPECTIVE COHORT STUDY IN SINGAPORE

Endoscopy in pancreatic NENs: Detection, RFA and beyond

Immunomodulation through neoadjuvant chemotherapy in pancreatic cancer

SHOULD PANCREATIC CANCER SURVEILLANCE BE OFFERED TO INDIVIDUALS WITH FAMILIAL ADENOMATOUS POLYPOSIS: RISK AND COST-EFFECTIVENESS ANALYSES